Los Angeles Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Los Angeles Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,260	Closed	-$321K	–	1431
2022 Q2	$321K	Buy	+4,260	New	+$189K	﹤0.01%	1127
2022 Q1	–	Sell	-6,929	Closed	-$331K	–	1528
2021 Q4	$331K	Sell	6,929 -83	-1%	-$3.71K	﹤0.01%	1207
2021 Q3	$466K	Sell	7,012 -4,190	-37%	-$298K	﹤0.01%	1073
2021 Q2	$874K	Buy	11,202 +317	+3%	+$23.4K	﹤0.01%	914
2021 Q1	$1.03M	Sell	10,885 -6,642	-38%	-$790K	﹤0.01%	881
2020 Q4	$2.14M	Buy	17,527 +175	+1%	+$19.2K	0.01%	635
2020 Q3	$1.52M	Buy	17,352 +11,537	+198%	+$804K	0.01%	662
2020 Q2	$376K	Buy	+5,815	New	+$335K	﹤0.01%	1219

Los Angeles Capital Management's TPTX Position: Q3 2022 in Review

Los Angeles Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 4,260 shares — an estimated $321K sold.

Los Angeles Capital Management first reported a position in TPTX in Q2 2020 and held it in 8 quarters. The position peaked at $2.14M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Los Angeles Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Los Angeles Capital Management sold 4,260 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $321K.
Los Angeles Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Los Angeles Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $2.14M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Los Angeles Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.